Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226901 | 0.88 | KMT2A (0.34) | ALDH1A1 | |
| SCHEMBL3216763 | 0.86 | PKM (0.31) | ALDH1A1TSHR | |
| SCHEMBL3216737 | 0.85 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL3216731 | 0.81 | S1PR1 (0.41) | ALDH1A1 | |
| SCHEMBL3213550 | 0.79 | KMT2A (0.35) | ALDH1A1TSHR | |
| SCHEMBL3222038 | 0.79 | L3MBTL1 (0.38) | ALDH1A1 | |
| SCHEMBL3226736 | 0.75 | NAAA (0.36) | — | |
| SCHEMBL4984736 | 0.72 | LMNA (0.31) | — | |
| SCHEMBL4887267 | 0.70 | AKR1B1 (0.55) | ALDH1A1 | |
| SCHEMBL3219719 | 0.69 | CHRM3 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | claimed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | claimed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | ALDH1A1 2093/4885TSHR 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.